Riposte: FDA response to 'Yin, yang and the biopharmaceutical industry'

Journal of Commercial Biotechnology

Volumn 10, Issue 1, 2003, Pages 36-39

  Rosenberg, Amy S ^a   Weiss, Karen D ^b   Lanthier, Michael ^c   Eastep, Roger ^a   Egan, William ^a   Goodman, Jesse L ^d   Woodcock, Janet ^d  

^a Center for Biologics Evaluation/Res   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c Center for Drug Evaluation/Research   (United States)

^d FDA's Center for Biol Eval/Res

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DNA VACCINE; ERYTHROPOIETIN; NEW DRUG; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT HEPATITIS B VACCINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BIOTECHNOLOGY; CLINICAL TRIAL; COMPETITION; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; DRUG SYNTHESIS; FOOD AND DRUG ADMINISTRATION; HEPATITIS B; HUMAN; IMMUNOGENICITY; LICENCE; MEDICAL TECHNOLOGY; POLICY; POSTMARKETING SURVEILLANCE;

EID: 3042733946     PISSN: 14628732     EISSN: None     Source Type: Journal    
DOI: 10.1057/palgrave.jcb.3040053     Document Type: Article

References (11)

1. Miller, H. L. (2003), 'Editorial: Yin, yang and the biopharmaceutical industry', J. Comm. Biotechnol., Vol. 9(4), 283-285.
2. Scrip (2002), No. 2808, p. 2.
3. URL: http://www.fda.gov/cder/present/MedianAPtime/index.htm
4. Miska, D. (2003), 'Biotech's twentieth birthday blues', Nature Rev. Drug Discovery, Vol. 2, pp. 231-233.
5. DiMasi, J. A., Hansen, R. W. and Grabowski, H. G. (2003), 'The price of innovation: New estimates of drug development costs', J. Health Economics, Vol. 22, pp. 151-185.
6. Frank, R. G. (2003), 'Editorial. New estimates of drug development costs', J. Health Economics, Vol. 22, pp. 325-330.
7. Tufts Center for the Study of Drug Development: Outlook 2002, Boston, Mass., USA.
8. Tufts Center for the Study of Drug Development: Outlook 2003, Boston, Mass., USA.
9. Casadevall, N., Nataf, J., Viron, B. et al. (2002), 'Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin', N Engl. J. Med., Vol. 346, pp. 469-475.
10. Gershon, S. K., Luksenburg, H., Cote, T. R. and Braun, M. M. (2002), 'Pure red cell aplasia and recombinant erythropoietin', N Engl. J. Med., Vol. 346, pp. 1584-1585.
11. Hilleman, M. R. (1987), 'Yeast recombinant hepatitis B vaccine', Infection, Vol. 15, p. 3.